MarketCap
Facebook
X
TelegramCatabasis Pharmaceuticals, Inc. Kurzfristige Verbindlichkeiten 2011-2026 | CATB
Kurzfristige Verbindlichkeiten Jährlich Catabasis Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 6.39 M | 5.03 M | 4.17 M | 6.02 M | 8.32 M | 7.81 M | 4.23 M | 2.93 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 8.32 M | 2.93 M | 5.61 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
4.59 M | $ 0.89 | - | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
1.83 M | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Exelixis
EXEL
|
406 M | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Harmony Biosciences Holdings
HRMY
|
252 M | $ 31.05 | - | $ 1.79 B | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
3.98 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
1.52 B | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
2 M | $ 0.7 | - | $ 1.71 M |  Canada |
 |
INmune Bio
INMB
|
8.42 M | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
49.7 M | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Jaguar Health
JAGX
|
40.7 M | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
57.4 M | $ 26.67 | - | $ 1.44 B |  Britain |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.98 | - | $ 4.91 M |  Israel |
 |
Krystal Biotech
KRYS
|
103 M | $ 259.95 | - | $ 7.52 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
37.1 M | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Liquidia Corporation
LQDA
|
136 M | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |